Apatinib in Advanced Non-squamous，NSCLC

Sponsor
Jian Fang
Study ID
NCT03376191
Status
Unknown

Conditions

  • Non-squamous Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • apatinib — DRUG
    Clinicians chose the initial dose of apatinib according to the patient's physical condition. Besides the clinicians adjusted the dose according to the patient's tolerance during the medication.The dosage was demanded not higher than 750 milligram (mg) per day. The patients received apatinib continuously, 28 days for a period, until intolerance, no longer getting benefits or patient wanted stop.

Study Details

To explore the efficacy and safety of apatinib in non-squamous non-small cell lung cancer in the real-world.

Key Dates

Start date
May 1, 2017
Status verified
Dec 2017
Primary completion
Apr 1, 2019
Completion
Oct 1, 2019

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

PFS (Progression-Free survival) [ Time Frame: From the date Into this study (signed ICF) to tumor progression or death for any reason，whichever came first, assessed up to 36 months ]

Related Studies